WSC 2022 | Should DAPT be given to all non-AF ischemic stroke patients?

Nijasri Suwanwela, MD, Chulalongkorn Comprehensive Stroke Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand, provides her perspective on whether dual antiplatelet therapy (DAPT) should be routinely given to all ischemic stroke (IS) patients that do not have atrial fibrillation (AF). Prof. Suwanwela believes that DAPT, consisting of aspirin and a P2Y12 inhibitor, should be given in these cases and can also include cilostazol for high-risk patients. This is because of data from the CHANCE (NCT00979589) and POINT (NCT00991029) clinical trials, whereby DAPT was given following minor IS or transient ischemic attack (TIA); and the CSPS.com (NCT01995370) clinical trial, testing the safety and efficacy of DAPT including cilostazol, in comparison with antiplatelet monotherapy. This interview took place at the World Stroke Congress 2022 in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.